

## OVERVIEW

- Focus on repurposing drugs for rare & infectious diseases
- Advancing clinical development of Bucillamine for infectious diseases, including COVID-19 (FDA Phase 3)
- Developing Psilocybin and Cannabidiol therapeutics for various CNS and inflammatory disorders
- Robust patent portfolio ([15 patents and patent applications](#))
- Awarded FDA Orphan Drug Status for CBD in the treatment of Autoimmune Hepatitis
- Prioritize development efforts targeting FDA regulatory incentives designations (i.e. Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease)
- Significantly undervalued compared to its peers


## PRODUCT PIPELINE

Product	Indication	Stage of Development	Regulatory Status
Bucillamine	Infectious Diseases COVID-19	Phase 3 (COVID-19)	FDA approved for Phase 3
Psilocybin	Substance Use Disorder Methamphetamine	Phase 1	CTA with University of Wisconsin
Psilocybin	Neurological TBI (Concussion), Stroke	Pre-clinical	Target FDA Orphan Drug Approval
Psilocybin (Oral Formulations)	Mental Health Depression, Anxiety	Pre-clinical	Target FDA Approval
Cannabidiol CBD	Liver Diseases Autoimmune Hepatitis	Filing IND	Plan for Phase 2


## UPCOMING MILESTONES

- Q1-21** Phase 3 COVID-19 interim study update (210 patients)
- Q1-21** Submit FDA IND for Phase 2 study for CBD in AIH
- Q1-21** Psilocybin oral thin film scale-up
- Q1-21** Psilocybin research results in TBI (Concussion)
- Q1-21** Begin Phase 1 study - Psilocybin in Meth Disorder
- Q2-21** Phase 3 COVID-19 Interim efficacy update (400 patients)
- Q2-21** Submit FDA IND for Psilocybin in TBI (Concussion)
- Q2-21** Initiate Phase 2 clinical study for CBD in AIH
- Q2-21** (End-Q2) Planned enrollment completion Phase 3 study COVID-19

## VALUATION COMPARISON



## STRATEGIC PARTNERS

 Infectious Diseases CRO	 Psilocybin Biosynthesis Collaboration	 R&D partnership Psychedelic pharma
 License of cannabidiol for treatment of Autoimmune Hepatitis	 License of cannabidiol delivery technology	 Psilocybin Collaboration

## TEAM

### Management

Michael Frank (Chairman & CEO)  
 Carmelo Marrelli (CFO)  
 Derrick Welch (Founder, Psilocin Pharma)

### Scientific and Clinical

Dr. Kelly McKee (CSO)  
 Dr. Osnesmo Mpanju (Regulatory)  
 Dr. John Fahy, MD (Clinical and Scientific Advisor)  
 Dr. Joel Moody, MD (Medical and Clinical Advisor)

### Directors

Michael Frank, William Jackson, Joshua Herman, Christian Scovenna and Andrew Lindzon

## STOCK INFORMATION

<b>Ticker:</b>	CSE: RVV, OTC: RVVTF, FRANKFURT: 31R
<b>Share Price:</b>	\$0.48 (Mar 5, 2021)
<b>52-week High / Low:</b>	CAD \$0.92 / \$0.075
<b>Shares Outstanding:</b>	315,634,551
<b>Market Cap:</b>	CAD ~ \$151,000,000